Delivery Order SPE2DB25D2204-SPE2DB25FTGTB
- Not listed
- The Defense Logistics Agency awarded a $43,110.46 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, with final delivery required by July 15, 2025. The contract was competitively awarded with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the delivery at its corporate office location. This delivery order is issued...
- The Defense Logistics Agency awarded a $9,183.92 delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on July 29, 2025, with a completion date of July 30, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a single delivery under AmerisourceBergen's broader pharmaceutical supply agreement with DLA. The product will be delivered to AmerisourceBergen's distribution facility in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency's Medical Supply Chain has awarded a delivery order valued at $7,810.81 to AmerisourceBergen Drug Corp for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, a pharmaceutical product used in the treatment of inflammatory conditions. The contract, issued on September 15, 2025, with an ultimate completion date of September 16, 2025, is structured as a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. Performance will take...
- The Defense Logistics Agency awarded a delivery order valued at $1,132.95 to AmerisourceBergen Drug Corp for HUMIRA Pen 40 mg/0.8 mL on August 5, 2025, with an ultimate completion date of August 6, 2025. This is a firm fixed price, competitively awarded delivery order with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is the place of performance for this contract. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $34,594.70 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mL on July 28, 2025, with a completion date of July 29, 2025. This non-competitive, firm fixed-price delivery order represents a fulfillment under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a total value of $999,999,999.00 through December 2026. The product will be delivered to...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, a specialty pharmaceutical product used in the treatment of autoimmune conditions. This firm fixed-price delivery order, valued at $11,500.66, is scheduled for completion by August 14, 2025, with performance to be executed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-aside...
- The Defense Logistics Agency awarded a $10,126.03 delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on April 21, 2025, with an ultimate completion date of April 22, 2025. This is a firm fixed-price, non-set-aside contract performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a single transaction under a larger indefinite delivery contract vehicle that enables AmerisourceBergen to supply pharmaceutical...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on May 22, 2025, for the supply of HUMIRA Pen 40 mg/0.8 mls, a biologic medication used to treat inflammatory conditions. This is a firm fixed-price delivery order with a ceiling value of $4,531.80 and an ultimate completion date of May 23, 2025. The contract is non-competitive with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a $9,400.49 delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mL on July 29, 2025, with an ultimate completion date of July 30, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The contractor will perform work at its corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $16,470.37 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mL on September 8, 2025, with an ultimate completion date of September 9, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. HUMIRA is a widely used biologic pharmaceutical for treating autoimmune and...
- SPE2DB25D2204Indefinite Delivery Contract
- SPE2DB25D2204-SPE2DB25FTGTBDelivery Order
The Defense Logistics Agency awarded a $17,711.94 delivery order to AmerisourceBergen Drug Corp for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL on July 14, 2025, with an ultimate completion date of July 15, 2025. This competitively awarded, firm fixed-price delivery order represents a routine pharmaceutical procurement under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement needs across military and veteran healthcare systems. This delivery order falls under AmerisourceBergen's prime indefinite delivery contract (IDC) SPE2DX with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. This comprehensive global pharmaceutical support vehicle enables AmerisourceBergen to supply a broad range of medications, vaccines, and medical supplies to support military healthcare programs worldwide. HUMIRA, a biologic immunosuppressant used to treat autoimmune conditions, represents the type of specialty pharmaceutical product that the company routinely furnishes through its federal contract portfolio, which demonstrates consistent capability in fulfilling open competition procurements ranging from small transactions to orders exceeding $45,000.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $17.7k | 7/14/25 |